Addition Of Trastuzumab To Carboplatin And Paclitaxel May Increase PFS, OS In Women With Advanced Or Recurrent HER2-Positive Uterine Serous Carcinoma
Healio (8/5, DeRosier) reports researchers found in a phase 2 trial that “the addition of trastuzumab to carboplatin and paclitaxel increased PFS and OS for women with advanced or recurrent HER2-positive uterine serous carcinoma.” In the trial, “researchers observed the greatest benefit among women with stage III and stage IV disease.” The findings were published in Clinical Cancer Research.